Crossmark

High-risk pulmonary embolism in the intensive care unit

Published Online: 2023-03-16

Published Print: 2023-05

Authors

Helms, Julie https://orcid.org/0000-0003-0895-6800
Carrier, Marc

Klok, Frederikus A.
License Information

Text and Data Mining valid from 2023-03-16

Version of Record valid from 2023-03-16
More Information

Article History

Received: 12 January 2023

Accepted: 16 February 2023

First Online: 16 March 2023

Declarations

:

: JH has received honoraria for lectures from Diagnostica Stago, Pfizer PFE France, Sanofi Aventis France, Inotrem, MSD and Shionogi, all unrelated to this work and paid to her institution. MC has received honoraria from Sanofi, Servier, BMS, Bayer, Pfizer and Leo Pharma and research funding from Leo Pharma, BMS, Pfizer, Canadian Institute of Health Research, Heart and Stroke Foundation of Canada, all unrelated to this work and all payment made to his institution. FAK reports grants or contracts from Bayer, BMS, BSCI, MSD, Leo Pharma, Actelion, Pharm-X, The Netherlands Organisation for Health Research and Development, the Dutch Thrombosis Association, The Dutch Heart Foundation and the Horizon Europe Program, all unrelated to this work and paid to his institution.

Document is current